OBJECTIVES : With the growing incidence of Endometrial cancer (EC), it is important to understand the disease effects, patient’s needs, therapies available, and what best can be done to improve the survival rates and quality of life of the patients. This study aimed to systematically review the efficacy and safety of available treatment options in patients with advanced, recurrent, or metastatic endometrial cancer.

METHODS : A comprehensive search strategy was developed to identify relevant articles in PubMed, Embase, and Cochrane from inception to 28 January 2021. A total of 6533 studies were identified and 5029 studies were retained after duplication. After title and abstract screening, 210 studies were processed to full-text screening, and 16 randomized controlled trials (RCTs) were included for this review. This review assessed overall survival (OS), progression-free survival (PFS), gastrointestinal and hematological adverse events from 16 RCTs studies. The study quality was tested by using the Cochrane Risk of Bias tool.

RESULTS : Across 16 studies analyzed, the median age of endometrial cancer patients was 60 years ± 6 years while the median follow-up time largely varied from 6 months to 7 years. The elderly population and post-menopausal women are most affected by endometrial cancer. Targeted therapy given in combination with chemotherapy was shown better survival rates (OS, PFS). Nausea, vomitings, and diarrhea are commonly observed gastrointestinal side effects. Anemia, Leukopenia, and Neutropenia are widely noticed hematological adverse events affecting the patient’s quality of life. Paclitaxel and Carboplatin were commonly used doublet chemotherapy regimens across the 16 RCTs, this regimen was as effective and safe compared to triplet treatment regimens.

CONCLUSIONS : Conventional chemotherapy drug regimens, double or triple-drug combinations are broadly used in advanced cases. The combination of targeted and chemotherapy may have promising results and it must be supported with future research.